Victoria Socha

DocwireNews

The FDA has granted <a title="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEyMTYuNTAzOTg1MjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L3BhdGllbnRzL2Zhc3QtdHJhY2stYnJlYWt0aHJvdWdoLXRoZXJhcHktYWNjZWxlcmF0ZWQtYXBwcm92YWwtcHJpb3JpdHktcmV2aWV3L2FjY2VsZXJhdGVkLWFwcHJvdmFsP3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.qkg_xSW1Ti5uFYmeALsxgrc19ie4uC37URxB6Q3BizE/s/1255995840/br/123254311032-l" contenteditable="false" href="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDEsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEyMTYuNTAzOTg1MjEiLCJ1cmwiOiJodHRwczovL3d3dy5mZGEuZ292L3BhdGllbnRzL2Zhc3QtdHJhY2stYnJlYWt0aHJvdWdoLXRoZXJhcHktYWNjZWxlcmF0ZWQtYXBwcm92YWwtcHJpb3JpdHktcmV2aWV3L2FjY2VsZXJhdGVkLWFwcHJvdmFsP3V0bV9tZWRpdW09ZW1haWwmdXRtX3NvdXJjZT1nb3ZkZWxpdmVyeSJ9.qkg_xSW1Ti5uFYmeALsxgrc19ie4uC37URxB6Q3BizE/s/1255995840/br/123254311032-l" target="_blank" rel="noopener">accelerated approval</a> for&#8239;<a title="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEyMTYuNTAzOTg1MjEiLCJ1cmwiOiJodHRwczovL3d3dy5hY2Nlc3NkYXRhLmZkYS5nb3YvZHJ1Z3NhdGZkYV9kb2NzL2xhYmVsLzIwMjEvMjE1OTM1czAwMGxibC5wZGY_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.zeE7GOjpYVmPsu-9ld2W7eqg8QIofmi-ktnI8uhVMVs/s/1255995840/br/123254311032-l" contenteditable="false" href="https://lnks.gd/l/eyJhbGciOiJIUzI1NiJ9.eyJidWxsZXRpbl9saW5rX2lkIjoxMDIsInVyaSI6ImJwMjpjbGljayIsImJ1bGxldGluX2lkIjoiMjAyMTEyMTYuNTAzOTg1MjEiLCJ1cmwiOiJodHRwczovL3d3dy5hY2Nlc3NkYXRhLmZkYS5nb3YvZHJ1Z3NhdGZkYV9kb2NzL2xhYmVsLzIwMjEvMjE1OTM1czAwMGxibC5wZGY_dXRtX21lZGl1bT1lbWFpbCZ1dG1fc291cmNlPWdvdmRlbGl2ZXJ5In0.zeE7GOjpYVmPsu-9ld2W7eqg8QIofmi-ktnI8uhVMVs/s/1255995840/br/123254311032-l" target="_blank" rel="noopener">Tarpeyo (budesonide) delayed release capsules</a> to reduce proteinuria (increased protein levels in the urine) in adults with primary immunoglobulin A (IgA) nephropathy at risk of rapid disease progression. It has not been established whether Tarpeyo slows kidney function decline in patients with IgA nephropathy.People who have allergic reactions to budesonide or any ingredients in Tarpeyo must not take the medication. Serious hypersensitivity reactions, including anaphylaxis (a severe, life-threatening allergic reaction) have occurred.Tarpeyo is a corticosteroid and can cause side effects similar to other corticosteroids, which include hypercortisolism (high levels of the cortisol hormone) and adrenal suppression (not able to produce enough cortisol). Patients with moderate to severe liver impairment may be at increased risk of these side effects.Tarpeyo is an immunosuppressant. As such, patients should not take Tarpeyo if they have tuberculosis; untreated fungal, bacterial, systemic viral or parasitic infections; or ocular herpes simplex (an eye infection). Patients taking Tarpeyo should avoid being exposed to active, easily transmitted infections. Corticosteroids, such as Tarpeyo, may decrease the immune response to some vaccines.The most common side effects of Tarpeyo are high blood pressure; swelling in the lower legs and hands; muscle spasms; acne; skin irritation; weight increase; difficulty breathing; face swelling; indigestion; fatigue; and excess hair, often around the nose and mouth.

Jordana Jampel

FDA Approves Novel Blood Test for Alzheimer’s Detection

Dementia

Andrew Moreno

Is Plasma Mannose-Binding Lectin a Clue to Higher VTE Risk?

Katie Kosko

EMBER-3: Imlunestrant Plus Abemaciclib Improves PFS in ER+ Breast Cancer

HR Breast Cancer

Latest News

Budesonide Gains FDA Approval for IgA Nephropathy

Nephrology Times

The FDA has granted accelerated approval for Tarpeyo (budesonide) delayed release capsules to reduce proteinuria (increased protein levels in the urine) in adults with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe